Published in Hepatitis Weekly, September 16th, 2002
The increase in revenue contributed to a 25% decrease in loss from operations to $12.3 million for the second quarter 2002 from $16.5 million for the same period in 2001. The increase in revenue was partially offset by increases in operating expenses in the second quarter 2002 compared with the same period in 2001.
The company's net loss applicable to common stock for the second quarter was $21.2 million, or $0.39 per share, compared with a net loss applicable to common...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.